Skip to main content
Top
Published in: Strahlentherapie und Onkologie 3/2017

01-03-2017 | Literatur kommentiert

Einfluss von Dosis und Fraktionierung auf die kurativ intendierte Strahlentherapie nicht-kleinzelliger Bronchialkarzinome

Author: Prof. Dr. med. Carsten Nieder

Published in: Strahlentherapie und Onkologie | Issue 3/2017

Login to get access

Auszug

In der Behandlung der nichtoperablen und nicht für die Stereotaxie (SBRT) geeigneten nicht-kleinzelligen Bronchialkarzinome (NSCLC) sind in den letzten Jahren vergleichsweise begrenzte Verbesserungen erzielt worden [1]. Die Radio- und Radiochemotherapie sind prinzipiell effektiv, bedürfen aber der Weiterentwicklung, um die lokale Kontrolle zu verbessern, wobei auch das häufig dosislimitierende Problem der Normalgewebetoleranz nicht aus den Augen gelassen werden darf [2]. Eine der wichtigen Fragen, die in klinischen Studien evaluiert werden, ist, inwieweit eine Dosiseskalation das Überleben verbessert. Falls dieser Effekt in kleineren Studien nicht eindeutig ausgeprägt sein sollte, können Metaanalysen eine klarere Antwort liefern. …
Literature
2.
go back to reference Guckenberger M, Kavanagh A, Partridge M (2012) Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol 188:894–900CrossRefPubMed Guckenberger M, Kavanagh A, Partridge M (2012) Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer. Strahlenther Onkol 188:894–900CrossRefPubMed
3.
go back to reference Ramroth J, Cutter DJ, Darby SCJ et al (2016) Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 96:736–747CrossRefPubMedPubMedCentral Ramroth J, Cutter DJ, Darby SCJ et al (2016) Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 96:736–747CrossRefPubMedPubMedCentral
4.
go back to reference Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199CrossRefPubMedPubMedCentral Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199CrossRefPubMedPubMedCentral
5.
go back to reference Willner J, Baier K, Caragiani E et al (2002) Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:382–389CrossRefPubMed Willner J, Baier K, Caragiani E et al (2002) Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:382–389CrossRefPubMed
6.
go back to reference Nyman J, Hallqvist A, Lund JÅ et al (2016) SPACE – A randomized study of SBRTvs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 121:1–8CrossRefPubMed Nyman J, Hallqvist A, Lund JÅ et al (2016) SPACE – A randomized study of SBRTvs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 121:1–8CrossRefPubMed
7.
go back to reference De Ruysscher D, Wanders R, van Haren E et al (2008) HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71:132–138CrossRefPubMed De Ruysscher D, Wanders R, van Haren E et al (2008) HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71:132–138CrossRefPubMed
8.
go back to reference Chen M, Hayman JA, Ten Haken RK et al (2006) Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys 64:120–126CrossRefPubMed Chen M, Hayman JA, Ten Haken RK et al (2006) Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? Int J Radiat Oncol Biol Phys 64:120–126CrossRefPubMed
9.
go back to reference Zhao J, Xia Y, Kaminski J et al (2016) Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized studies. PLOS ONE 11:e0157455CrossRefPubMedPubMedCentral Zhao J, Xia Y, Kaminski J et al (2016) Treatment-related death during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized studies. PLOS ONE 11:e0157455CrossRefPubMedPubMedCentral
10.
go back to reference Zschaeck S, Simon M, Löck S et al (2016) PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. Trials 17:543CrossRefPubMedPubMedCentral Zschaeck S, Simon M, Löck S et al (2016) PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. Trials 17:543CrossRefPubMedPubMedCentral
11.
go back to reference Brower JV, Amini A, Chen S et al (2016) Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. Ann Oncol 27:1887–1894CrossRefPubMed Brower JV, Amini A, Chen S et al (2016) Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database. Ann Oncol 27:1887–1894CrossRefPubMed
Metadata
Title
Einfluss von Dosis und Fraktionierung auf die kurativ intendierte Strahlentherapie nicht-kleinzelliger Bronchialkarzinome
Author
Prof. Dr. med. Carsten Nieder
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 3/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1096-y

Other articles of this Issue 3/2017

Strahlentherapie und Onkologie 3/2017 Go to the issue